Sjögren's drug shows promise in safety extension trial
NCT ID NCT06203457
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at the long-term safety of efgartigimod in 24 adults with primary Sjögren's syndrome who had already completed a prior trial. Efgartigimod works by lowering certain antibodies that may drive the disease. The main goal was to track side effects over 48 weeks, with a secondary look at whether symptoms improved.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
efgartigimod
What this could lead to
If it works, this could point toward a treatment that reduces disease activity and symptoms in Sjögren's syndrome.
What could go wrong
This is a small, early-phase safety extension study, not designed to prove effectiveness. The drug may not improve symptoms and carries risks like infections due to lowered antibody levels.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PRIMARY SJÖGREN'S SYNDROME are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centrum Medyczne Plejady
Krakow, 30 363, Poland
-
Centrum Medyczne Pratia Poznan
Skorzewo, 60 185, Poland
-
Clinical Research Center Spółka z ograniczoną odpowiedzialnością Medic-R Sp.k.
Poznan, 60-848, Poland
-
Debreceni Egyetem
Debrecen, 4032, Hungary
-
FutureMeds sp zoo
Wroclaw, 50 088, Poland
-
Klinika Reuma Park Sp zoo Sp K
Warsaw, 02 665, Poland
-
MCBK SC
Grodzisk Mazowiecki, 05 825, Poland
-
MICS Centrum Medyczne Warszawa
Warsaw, 00 874, Poland
-
Narodowy Instytut Geriatrii
Warsaw, 02637, Poland
-
Universitair Ziekenhuis Gent
Ghent, 9000, Belgium
-
Vita Verum Medical Egeszsegugyi Szolgaltato Bt.
Székesfehérvár, 8000, Hungary